Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) rose 5.1% on Thursday . The stock traded as high as $0.73 and last traded at $0.72. Approximately 697,256 shares changed hands during trading, a decline of 85% from the average daily volume of 4,557,864 shares. The stock had previously closed at $0.69.
Analyst Ratings Changes
IVVD has been the subject of several recent analyst reports. D. Boral Capital reaffirmed a "buy" rating and set a $9.00 price objective on shares of Invivyd in a report on Thursday, June 26th. HC Wainwright reaffirmed a "buy" rating and set a $5.00 price objective on shares of Invivyd in a report on Thursday, June 26th.
Read Our Latest Stock Analysis on IVVD
Invivyd Price Performance
The company's 50 day moving average price is $0.79 and its 200 day moving average price is $0.78. The firm has a market capitalization of $89.97 million, a P/E ratio of -0.62 and a beta of 0.52.
Invivyd (NASDAQ:IVVD - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.10). Invivyd had a negative net margin of 389.01% and a negative return on equity of 165.24%. The company had revenue of $11.30 million for the quarter, compared to the consensus estimate of $34.45 million. On average, research analysts anticipate that Invivyd, Inc. will post -1.64 EPS for the current fiscal year.
Institutional Trading of Invivyd
Hedge funds have recently modified their holdings of the stock. Jane Street Group LLC grew its stake in shares of Invivyd by 290.5% during the fourth quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock valued at $52,000 after purchasing an additional 87,358 shares during the last quarter. Barclays PLC grew its stake in shares of Invivyd by 7.8% during the fourth quarter. Barclays PLC now owns 127,180 shares of the company's stock valued at $56,000 after purchasing an additional 9,207 shares during the last quarter. Nuveen LLC bought a new stake in shares of Invivyd during the first quarter valued at approximately $65,000. Invesco Ltd. boosted its stake in Invivyd by 190.6% in the first quarter. Invesco Ltd. now owns 108,999 shares of the company's stock valued at $66,000 after acquiring an additional 71,485 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in Invivyd in the first quarter valued at approximately $66,000. 70.36% of the stock is owned by institutional investors.
About Invivyd
(
Get Free Report)
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.
Recommended Stories
Before you consider Invivyd, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Invivyd wasn't on the list.
While Invivyd currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
